Drug Profile
Eganelisib - Infinity Pharmaceuticals
Alternative Names: IPI-549Latest Information Update: 12 Jul 2023
Price :
$50
*
At a glance
- Originator Intellikine
- Developer Arcus Biosciences; Bristol-Myers Squibb; Infinity Pharmaceuticals; University of California, San Diego
- Class Amides; Amines; Antineoplastics; Isoquinolines; Pyrazoles; Pyrazolones; Pyrimidines; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase gamma inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Head and neck cancer; Renal cell carcinoma; Triple negative breast cancer; Urogenital cancer
- Preclinical Non-small cell lung cancer
- No development reported Ovarian cancer; Solid tumours
Most Recent Events
- 10 Jul 2023 Infinity Pharmaceuticals receives FDA feedback on the phase II MARIO-8 trial for Head and neck squamous cell carcinoma
- 18 Apr 2023 Preclinical trials in Non-small cell lung cancer in USA (PO) as of April 2023
- 13 Apr 2023 Pharmacodynamics data from a preclinical trial in Head and neck cancer and Non small cell lung cancer released by Infinity Pharmaceuticals